Table 1 Clinical information from patients with urinary samples that contained high levels of type-1 free-N-glycan having Lewis B antigen.

From: Identification of a free-N-glycan with difucosylated type-1 lactosamine in cancerous tissue and its validation for cancer diagnosis by urinary testing

No.

Age

Sex

Blood type

Cancer diagnosis

Stage

Metastasis

CA19-9

(U/ml)

CEA

(ng/ml)

AFP

(ng/ml)

1

64

M

A

AFP-producing gastric cancer

IV

Multiple lymph node and liver metastases

66

753.4

622

2

64

F

A

Descending colon cancer

IV

Multiple bone and brain metastases

6

3.5

3

3

74

M

B

Neuroendocrine carcinoma

IV

Lymph node and liver metastases

n.a

3.5

n.a

4

34

F

O

Scirrhous gastric cancer

IV

Multiple lymph node metastases, peritoneal dissemination

68

1.6

2

5

63

F

n.a

Ascending colon cancer

IV

Multiple liver metastases

8

7.3

n.a

  1. n.a. is not available.
  2. The cut-off values for CA19-9, CEA, and AFP were 37 units/ml, 5 ng/ml, and 10 ng/ml, respectively.
  3. No. indicates the order of the highest value of free-N-glycans with Lewis B antigen detected in the urine samples.
Back to article page